Evidence-Based Medicine
What Is GLP-1 Therapy?
GLP-1 receptor agonists are a class of medications that work with your body’s own hormonal system to regulate blood sugar, suppress appetite, and drive sustained metabolic improvement. They are not stimulants. They correct the underlying hormonal environment that makes weight loss difficult — and in many cases, physiologically impossible through diet and exercise alone when occupational stressors remain in place.
GLP-1 therapy is not a trend. It is the most evidence-backed metabolic intervention available today.
Clinical Trial Outcomes
From large-scale, peer-reviewed trials — not marketing claims.
20.2%
Tirzepatide Weight Loss
Average body weight reduction in the SURMOUNT trials — the highest recorded in any GLP-1 class medication.
13.7%
Semaglutide Weight Loss
Average body weight reduction with simultaneous improvements in blood pressure, insulin sensitivity, and cardiovascular risk.
94%
Diabetes Prevention
Reduction in progression to type 2 diabetes with Tirzepatide (SURMOUNT-5). 73% with Semaglutide. Both are clinically significant.
15–20%
Cardiac Risk Reduction
Reduction in major cardiovascular events in high-risk populations — directly relevant to first responders, CDL, and military.
Tirzepatide vs. Semaglutide
Both medications are clinically proven. Here is why Tirzepatide is our first-line recommendation.
Tirzepatide — GIP/GLP-1 Dual Agonist
- Mechanism: Activates both GIP and GLP-1 receptors — dual hormonal action producing superior metabolic outcomes.
- Weight Loss: 20.2% average reduction — highest recorded in class.
- GI Tolerability: Nausea rates 24–33% vs. 43.9% with Semaglutide. Half the vomiting rate. Critical for CDL holders and operational professionals.
- Diabetes Prevention: 94% reduction in progression to type 2 diabetes (SURMOUNT-5).
- First-Line Choice: Recommended as the primary medication at Overwatch Metabolics.
Semaglutide — GLP-1 Agonist
- Mechanism: Activates the GLP-1 receptor, regulating appetite, blood sugar, and gastric emptying.
- Weight Loss: 13.7% average reduction — clinically meaningful and well-established.
- GI Tolerability: Nausea rates of 43.9% — more common than Tirzepatide during dose titration.
- Diabetes Prevention: 73% reduction in progression to type 2 diabetes — a strong clinical outcome.
- When We Use It: Appropriate for specific clinical indications or individual patient response.
Six Mechanisms. One Clinical Result.
Why GLP-1 therapy produces results that diet and exercise alone cannot replicate when the hormonal environment is disrupted.
Appetite Suppression
GLP-1 receptors in the hypothalamus signal satiety — reducing hunger without requiring willpower to override biological hunger signals created by chronic stress and shift work.
Blood Sugar Regulation
Stimulates insulin secretion in response to meals and suppresses glucagon — stabilizing blood glucose and reducing the metabolic damage of chronic hyperglycemia common in shift workers.
Gastric Emptying
Slows the rate at which the stomach empties — extending the sensation of fullness after meals and reducing post-meal glucose spikes during high-demand shifts.
Blood Pressure Reduction
Clinical data shows a 4–10 mmHg reduction in systolic blood pressure — meaningful for patients near hypertension thresholds, including CDL holders at DOT certification risk.
Systemic Inflammation
GLP-1 therapy reduces markers of systemic inflammation — addressing joint degeneration, chronic pain, and the metabolic consequences of sustained occupational and psychological stress.
Insulin Sensitivity
Improves insulin sensitivity by 30–40% — reversing the core driver of metabolic syndrome, prediabetes, and abdominal fat accumulation caused by shift work and chronic cortisol exposure.
Why It Matters for High-Demand Professions
The Hormonal Environment
The Reality: Shift work, chronic cortisol exposure, sleep fragmentation, and sustained psychological stress create a hormonal environment that actively promotes fat storage and impairs insulin sensitivity.
The Impact: Diet and exercise cannot reliably overcome a dysregulated hormonal environment. This is physiology — not a failure of effort. GLP-1 therapy corrects the hormonal drivers that behavioral approaches alone cannot address.
The Population-Level Data
First Responders: 77–90% overweight or obese. Cardiac events account for 45–50% of all line-of-duty deaths. Metabolic syndrome prevalence 2× the general population.
CDL Drivers: 69% obesity rate vs. 31% national average. Average life expectancy 61 years — 18 years below average. 52.4% metabolic syndrome prevalence.
Military: 69% of active duty overweight or obese. Clinical obesity up 65% since 2013 despite mandatory fitness standards.
About the Founders
Overwatch Metabolics was founded by Daniel Nobles and his wife, Lori Nobles — united by a shared commitment to delivering evidence-based metabolic care with compassion, integrity, and purpose.
Daniel brings more than 30 years of clinical experience, including a residency in Emergency Medicine and an academic appointment in Neurosurgery. Together, Daniel and Lori have built a GLP-1 and wellness practice that has treated more than 1,000 patients over the past 2.5 years.
